Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic HSCT for GATA2 Mutations or MonoMAC Syndrome
NCT01861106Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2013
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial of allogeneic hematopoietic stem cells in GATA2 deficiency (GATA2D) and Monocytopenia And Mycobacterial Infection Syndrome (MonoMAC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Engraftment and restoration of normal hematopoiesis at 1 year. Started Jul 2013; status: recruiting.
02
Drugs
allogeneic hematopoietic stem cells
03
Conditions
GATA2 deficiency (GATA2D)Monocytopenia And Mycobacterial Infection Syndrome (MonoMAC)
Beyond the preview
Go deeper on NCT01861106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01861106.